Q-omics provides the consensus-scored UBR4 profile across patient tissues and cancer cell-line models. UBR4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBR4 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, UBR4 RNA expression shows 20,660 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where UBR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBR4 survival associations across molecular data types. UBR4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (15) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBR4 RNA expression–survival associations across cancer types. High UBR4 expression shows unfavorable associations in ACC, LIHC, LGG and LUSC, but favorable associations in SCLC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBR4 RNA expression.
This table summarizes UBR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UBR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBR4 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, STAD, LUSC and LIHC. The HNSC box plot shows higher UBR4 RNA expression in tumor versus normal tissue (log2 FC = +0.650, t-test p < 0.001).
This table shows molecular features associated with UBR4 in patient tissues and cancer cell lines. In patient samples, UBR4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
